Business and Financial Advisor:• Providing financial, business and strategic advisory services to various startup entities: medical device (cardiology, gastroenterology, stem cell and diagnostics), biotechnology, software and alternative energy related companies, etc. • Services range from facilitating startups in establishing appropriate internal controls, administrative procedural processes, writing and critiquing business plans/strategies, preparation of company presentations, short-term financial operating plans, long-term strategic financial planning, assist organizations with seeking financing and advise in various negotiations related to mergers and acquisitions, distribution rights, technology licensing and other business structural issues, review and implementation of internal control structures in support of Sarbanes Oxley compliance.

AMBS (OTCBB) is a public development-stage biotechnology company founded in January 2008, focused on the development of therapeutic applications for its proprietary protein, known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF”), which corrects protein misfolding, one of the major causes of apoptosis (cell death).• Responsible for all finance and accounting matters, including SEC filings and related matters• Took company public via a reverse merger and recapitalization

Neoguide Systems Inc. was developing a way to perform robotic endoscopic technology for natural orifice transluminal endoscopic surgery. Its technology is used in colonoscopy application to provide access to abdominal and thoracic cavities.Position: Consulting, Chief Financial Officer• Responsible for all financial and accounting matters• Oversaw company audits.• Develop business plans and funding presentations as well as board presentations.• Led project to transition from QuickBooks to QED to better manage production, parts traceability, and inventory, for compliance with CE mark and FDA regulations.

FlowMedica Inc. was a venture backed, privately held commercial-stage company focused on the prevention and treatment of kidney dysfunction resulting from certain cardiovascular, endovascular, or surgical procedures and disease states.

EnReach Technology Inc. was a privately held company providing IP infrastructure software to deliver integrated voice, video, and data solutions and services to the television.• Designed international corporate structures, involving the United States, Canada, PRC China and Hong Kong• Created multiple subsidies and inter-company license agreements in Hong Kong and Beijing, and Canada• Involved in various licensing agreements leveraging the company’s core technology• Implemented international tax strategy, involving the United States, Canada, PRC China and Hong Kong• Spun out entities to shareholders in a tax free distribution• Closed $8M Series B financing

Norian Corporation was a private medical device company, acquired by Synthes USA, June 1999.Positions: Chief Financial Officer, President and Chief Executive Officer, and Board of Directors MemberPromoted to the positions of President and Chief Executive Officer on an interim basis in June 1998 and permanently in November 1998, as well as being elected to the board of directors. Led the Company through a period of unsettling re-organization, consolidation and eventual sale of the Company. Raised $37.7 million of additional financing, going from a post-money market capitalization of $31.4 million in 1991 to $124.4 million in early 1998.• Led Company through eventual sale while retaining all key employees• Developed a flexible management style focused on creating win-win situations instilling trust with the employees• Proven ability to deal with crisis and accept unanticipated changes while instilling confidence in employees• Closed on various financing rounds totaling $37.7 million cumulatively and technology licensing agreements with a Japanese dental company and a US trauma hardware company• Demonstrated ability to work with Wall Street analysts and corporate investment bankers, through the IPO process, road show and investment banker industry conference presentations• Strategically focused on the future and building the necessary infrastructure for growth in Europe, Asia and US.

• Reorganized and rebuilt the finance organization, recruiting senior financial staff• Spearheaded the Company’s international expansion into eleven countries simultaneously, the President presented the outcome to the Board as a “seamless effort”• Establish Company currency hedging program and international banking structure• Instrumental in corporate restructurings (spin-offs, discontinued operations, and stock offerings – coordinating attorneys, independent accounts and responding to SEC inquires• Critical to the negotiations and implementation of the buy back of the international distributor agreement

• Streamlined global consolidation and external reporting processes (actual, forecast, budgets and SEC reporting)• Reduced independent accountant’s efforts and fees by 40%+• Managed 2x ramping of business within a four month period without interruption in services• Simplified routine processes resulting in significant infrastructure cost reductions in excess of $3 million per annum through the implementation of quality processes• Re-engineered processes resulting in operations ability to more than quadruple their transaction volume without additional staff

• Created and implemented complex program to minimize consolidated taxable income for parent cash basis books, resulting in over $10 million of tax savings• Designed and instituted internal control procedures at commodities and distribution subsidiaries

Worked on the audit of financial institutions, jewelry industry, and various other manufacturers.